T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy

Transplantation. 2016 Mar;100(3):e8-e10. doi: 10.1097/TP.0000000000001099.

Authors

Mira Choi¹, Susanne Fink, Vikas Prasad, Ioannis Anagnostopoulos, Petra Reinke, Clemens A Schmitt

Affiliation

¹ 1 Department of Nephrology and Intensive Care Medicine, Charité, Berlin, Germany. 2 Department of Nephrology, University of Heidelberg, Heidelberg, Germany. 3 DKFZ unit F100, Heidelberg, Germany. 4 Department of Nuclear Medicine, Charité, Berlin, Germany. 5 Institute of Pathology, Charité, Berlin, Germany. 6 Department of Hematology, Oncology and Tumor Immunology, Charité, Berlin, Germany.

PMID: 26900813
DOI: 10.1097/TP.0000000000001099

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biopsy
Brentuximab Vedotin
Female
Humans
Immunoconjugates / adverse effects
Immunoconjugates / therapeutic use*
Immunohistochemistry
Immunosuppressive Agents / adverse effects
Kidney Transplantation / adverse effects*
Lymphoma, T-Cell / diagnosis
Lymphoma, T-Cell / drug therapy*
Lymphoma, T-Cell / immunology
Middle Aged
Off-Label Use
Positron-Emission Tomography
Remission Induction
Time Factors
Tomography, X-Ray Computed
Treatment Outcome

Substances

Antineoplastic Agents
Immunoconjugates
Immunosuppressive Agents
Brentuximab Vedotin